SAFE Sunscreen Standards Act

Bill Number

H.R. 3686

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-06-03: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-11T23:26:37Z

AI-Generated Summary

Purpose of the Legislation

The SAFE Sunscreen Standards Act aims to streamline and modernize the Food and Drug Administration's (FDA) review process for nonprescription sunscreen active ingredients. By updating safety and effectiveness evaluations, the bill seeks to increase access to innovative sunscreens, addressing the rising incidence of skin cancer in the United States and promoting public health through better sun protection.

Key Provisions

• Findings on Skin Cancer and Sunscreen Needs: The bill outlines Congress's recognition of skin cancer as the most common cancer in the U.S., affecting millions annually with high costs and mortality rates. It highlights the preventive role of sunscreens (e.g., broad-spectrum with SPF 30 or higher) amid rising UV exposure, and notes the lack of new sunscreen approvals since 1999 despite the 2014 Sunscreen Innovation Act.

• Updated Standards for Sunscreen Reviews (SEC. 3):
• Requires the FDA to create guidelines or rules for assessing sunscreen active ingredients' safety and effectiveness.
• Allows use of real-world evidence (data from everyday use), observational studies (non-experimental health data), and other valid methods to supplement or replace traditional clinical trials.
• Permits non-animal testing alternatives, such as lab-based or computer-model methods, drawing from recent laws on drug testing.
• Mandates FDA guidance on non-animal testing within 180 days of enactment.

• Final Administrative Order on Pending Submissions (SEC. 4):
• Directs the FDA's ongoing review of submitted sunscreen ingredients to consider historical safety data from previously marketed products.
• Emphasizes sunscreens as a key tool for preventing skin cancer.
• Requires incorporation of the new evidence and testing standards.

• Reporting and Transparency Requirements (SEC. 5):
• Obligates the Secretary of Health and Human Services (overseeing the FDA) to submit annual reports to Congress starting one year after enactment, covering implementation of new standards, application reviews, and progress on non-animal testing.
• Requires public posting of these reports on the FDA website within seven days.

Significant Changes to Existing Law

• Amends Section 505G of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which governs over-the-counter drugs like sunscreens, by adding a new subsection (r) on sunscreen-specific standards.
• Builds on the 2014 Sunscreen Innovation Act by introducing flexible evidence options (e.g., real-world data) and non-animal testing, potentially accelerating approvals beyond the current rigid clinical trial requirements.
• Updates the 2020 CARES Act's framework for reviewing pending sunscreen submissions, integrating historical data and prevention-focused language not previously emphasized.

Potential Impacts

• On Government Agencies: The FDA will face new obligations to develop guidance, review applications under updated standards, and report annually, potentially increasing workload but enabling more efficient processes and reduced reliance on animal testing.
• On Citizens: Could lead to faster availability of safe, effective sunscreens, improving access to sun protection and potentially lowering skin cancer rates (e.g., preventing 80% of cases through better habits, per WHO estimates). Benefits young adults and all ages at risk from rising UV exposure.
• On International Relations: Minimal direct impact, though it may encourage global alignment on sunscreen innovation and non-animal testing standards, indirectly supporting U.S. leadership in public health.

Main Stakeholders Affected

• Sunscreen Manufacturers and Sponsors: Gain clearer pathways for submitting and approving new active ingredients using modern evidence, reducing time and costs for innovation.
• Consumers and Public Health Advocates: Benefit from enhanced sunscreen options to combat skin cancer, with emphasis on prevention.
• FDA and Health Agencies: Responsible for implementation, testing alternatives, and transparency reporting.
• Congressional Committees: Energy and Commerce (House) and Health, Education, Labor, and Pensions (Senate) receive oversight reports to monitor progress.
• Environmental and Animal Welfare Groups: Positively affected by promotion of non-animal testing methods.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens the FD&C Act's framework for over-the-counter drugs by incorporating real-world evidence (defined in the 2017 FDA user fee reauthorization) and non-animal alternatives from the 2022 health omnibus law, potentially setting precedents for flexible drug reviews without compromising safety. Ensures "prima facie" (initial evidence of) safety for nonprescription use.
• Constitutional: No apparent challenges; aligns with Congress's authority under the Commerce Clause to regulate drugs affecting interstate commerce and public health.
• Political: Bipartisan sponsorship (e.g., Republicans and Democrats) reflects unanimous prior support for sunscreen innovation. Promotes public health priorities like cancer prevention amid environmental concerns (rising UV index), but could face scrutiny over balancing innovation speed with rigorous safety if approvals increase.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Joyce, John [R-PA-13]

Cosponsors (9)

Rep. Dingell, Debbie [D-MI-6], Rep. Joyce, David P. [R-OH-14], Rep. Ross, Deborah K. [D-NC-2], Rep. Goldman, Craig A. [R-TX-12], Rep. Auchincloss, Jake [D-MA-4], Rep. Swalwell, Eric [D-CA-14], Rep. James, John [R-MI-10], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Neguse, Joe [D-CO-2]

Recent Actions

• 2025-06-03: Referred to the House Committee on Energy and Commerce.
• 2025-06-03: Introduced in House
• 2025-06-03: Introduced in House

Bill Versions

• Supporting Accessible, Flexible, and Effective Sunscreen Standards — issued 2025-06-03 — PDF (7 pages)